{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:16:32Z","timestamp":1792790192779,"version":"4.5.0"},"reference-count":41,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>OnabotulinumtoxinA is an FDA-approved treatment for adults with overactive bladder (OAB) who have an inadequate response to, or are intolerant of, oral pharmacotherapies including anticholinergics or beta-3 agonists. However, procedural practices of onabotulinumtoxinA intradetrusor injection vary among practitioners and can affect patient experience. To address this, a panel of six high-volume intravesical onabotulinumtoxinA providers with 100 years of combined experience convened to discuss the best office practices when treating patients with OAB. These key best practices include counseling patients on available OAB therapies, including onabotulinumtoxinA, at the initial consultation in accordance with established AUA and SUFU guidelines in a way that is easily understood. An office setting is preferred over a hospital or surgery center when performing the procedure. Staff involvement, from scheduling to post-procedure, is essential for establishing the relationships necessary to optimize patient experience and encourage compliance and retreatment. Experts generally recommend using a viscous lidocaine bladder instillation for an anesthetic 15 min prior to the reconstitution of onabotulinumtoxinA with 5 to 10 mL of normal saline. A range of one to 20 injection sites is acceptable, with a smaller number preferred. Starting in the lower bladder, experts recommend using a slower speed of injection to improve distribution and decrease patient discomfort. Subsequent treatments should be regularly scheduled at six-month intervals with the option of re-treating earlier if symptoms return, but no sooner than 12 weeks. For office intravesical onabotulinumtoxinA procedures, optimization of the patient experience by the physician and their staff, starting with the initial visit through the post-treatment follow-up, is key to long-term patient compliance.<\/jats:p>","DOI":"10.3390\/toxins17040207","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T20:38:26Z","timestamp":1745267906000},"page":"207","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expert Opinions on Best Practices for Overactive Bladder Management with onabotulinumtoxinA"],"prefix":"10.3390","volume":"17","author":[{"given":"Karyn S.","family":"Eilber","sequence":"first","affiliation":[{"name":"Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Brucker","sequence":"additional","affiliation":[{"name":"Departments of Urology and Obstetrics and Gynecology, New York University Langone Health, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pezzella","sequence":"additional","affiliation":[{"name":"Southern Urogynecology Wellness and Aesthetics, West Columbia, SC 29169, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lucente","sequence":"additional","affiliation":[{"name":"Axia Women\u2019s Health, The Institute for Female Pelvic Medicine & Reconstructive Surgery, FPM Urogynecology Center, Allentown, PA 18103, USA"},{"name":"Division of Gynecology, Section of Urogynecology, St. Luke\u2019s University Health Network, Bethlehem, PA 18015, USA"},{"name":"Department of Obstetrics and Gynecology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Benson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Urogynecology and Pelvic Surgery, Sanford University of South Dakota Medical Center and Hospital, Sioux Falls, SD 57105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kennelly","sequence":"additional","affiliation":[{"name":"Department of Urology, Atrium Health Wake Forest University School of Medicine, Carolinas Medical Center, Charlotte, NC 28203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the international continence society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The aua\/sufu guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"212","author":"Cameron","year":"2024","journal-title":"J. Urol."},{"key":"ref_3","unstructured":"Abbvie (2024, June 21). Botox [Package Insert]. U.S. Food and Drug Administration Website. Revised August 2023, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/103000orig1s5325correctedlbl.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"Onabotulinumtoxina for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term onabotulinumtoxina treatment in patients with overactive bladder syndrome: Final results of a 3.5-year study","volume":"196","author":"Nitti","year":"2016","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"Onabotulinumtoxina 100 u significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5213\/inj.2015.19.4.213","article-title":"Practical aspects of botulinum toxin-a treatment in patients with overactive bladder syndrome","volume":"19","author":"Liao","year":"2015","journal-title":"Int. Neurourol. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/nau.22780","article-title":"Different number of intravesical onabotulinumtoxina injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study","volume":"35","author":"Liao","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/nau.23052","article-title":"Less is more-a pilot study evaluating one to three intradetrusor sites for injection of onabotulinumtoxina for neurogenic and idiopathic detrusor overactivity","volume":"36","author":"Avallone","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/nau.25107","article-title":"Reduced versus standard intradetrusor onabotulinumtoxina injections for treatment of overactive bladder","volume":"42","author":"Dengler","year":"2023","journal-title":"Neurourol. Urodyn."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.ajog.2022.05.025","article-title":"Oral phenazopyridine vs intravesical lidocaine for bladder onabotulinumtoxina analgesia: A randomized controlled trial","volume":"227","author":"Stewart","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00192-020-04230-7","article-title":"A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin a injection","volume":"31","author":"Bickhaus","year":"2020","journal-title":"Int. Urogynecol. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ogc.2015.10.002","article-title":"Overactive bladder","volume":"43","author":"White","year":"2016","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/nau.25046","article-title":"An analysis of factors that influence patient preference of third-line therapy for overactive bladder","volume":"41","author":"Kapur","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1016\/S1569-9056(13)61223-3","article-title":"Pivotal phase 3 study in overactive bladder (oab) patients with urinary incontinence confirms onabotulinumtoxina 100u significantly improves all oab symptoms and patients\u2019 quality of life","volume":"1","author":"Chapple","year":"2013","journal-title":"Eur. Urol. Suppl."},{"key":"ref_16","first-page":"2","article-title":"Expert consensus guidance on appropriate management of incomplete voiding of the bladder post-onabotulinumtoxina injection in patients with idiopathic overactive bladder","volume":"8","author":"Kennelly","year":"2020","journal-title":"EMJ Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.euros.2023.09.013","article-title":"The effects of age, gender, and postvoid residual volume on catheterization rates after treatment with onabotulinumtoxina for overactive bladder","volume":"57","author":"Dmochowski","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxina in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/nau.25538","article-title":"Efficacy and safety of onabotulinumtoxina for the treatment of overactive bladder in men and women: A pooled analysis","volume":"43","author":"Nitti","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101227","DOI":"10.1016\/j.cont.2024.101227","article-title":"Bladder onabotulinum toxin a injections and patients: Office-based vs. Operating room setting","volume":"10","author":"Bianchi","year":"2024","journal-title":"Continence"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/end.2022.0210","article-title":"Clinical utility of a single-use flexible cystoscope compared with a standard reusable device: A randomized noninferiority study","volume":"37","author":"Holmes","year":"2023","journal-title":"J. Endourol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.urology.2022.05.039","article-title":"Cost-effectiveness of 90-day single-use flexible cystoscope trial: Single center micro-costing analysis and user satisfaction","volume":"167","author":"Assmus","year":"2022","journal-title":"Urology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1007\/s00330-022-09230-3","article-title":"Effects of aromatherapy and music therapy on patients\u2019 anxiety during MRI examinations: A randomized controlled trial","volume":"33","author":"Wen","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_24","first-page":"555647","article-title":"Verbal anesthesia: How and when to use it in urological procedures","volume":"4","author":"Gange","year":"2018","journal-title":"JOJ Urol. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zargari Marandi, R., Fjelsted, C.A., Hrustanovic, I., Dan Olesen, R., and Gazerani, P. (2020). Eye movements in response to pain-related feelings in the presence of low and high cognitive loads. Behav. Sci., 10.","DOI":"10.3390\/bs10050092"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/JU.0000000000000509","article-title":"Best practice statement on urologic procedures and antimicrobial prophylaxis","volume":"203","author":"Lightner","year":"2020","journal-title":"J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00192-021-04691-4","article-title":"Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder","volume":"33","author":"Eckhardt","year":"2022","journal-title":"Int. Urogynecol. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/nau.24758","article-title":"Intravesical onabotulinumtoxina injections in patients on antiplatelet and anticoagulation therapy","volume":"40","author":"Mensah","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_29","first-page":"6649","article-title":"Intradetrusor onabotulinumtoxina injection: How I do it","volume":"20","author":"Shenot","year":"2013","journal-title":"Can. J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.25290","article-title":"Efficacy and safety of an alternative onabotulinumtoxina injection paradigm for refractory overactive bladder","volume":"43","author":"MacDiarmid","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107368","DOI":"10.1016\/j.toxicon.2024.107368","article-title":"Patient persistence to onabotulinumtoxina treatment for overactive bladder using a reduced-injection-site paradigm: A retrospective chart review study","volume":"237","author":"Bernstein","year":"2024","journal-title":"Toxicon"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s11255-021-02802-0","article-title":"Outcomes of a single trigone-only vs. 20 trigone-sparing injections of onabotulinumtoxina for refractory overactive bladder (oab)","volume":"53","author":"Ton","year":"2021","journal-title":"Int. Urol. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cui, Y., Cai, T., Dong, T., Zhang, X., Zhou, Z., Lu, Y., Zhang, Y., Wu, J., Gao, Z., and Wang, Y. (2021). Trigonal-sparing vs. Trigonal-involved onabotulinumtoxina injection for the treatment of overactive bladder: A systematic review and meta-analysis. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.651635"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/nau.23049","article-title":"A three dimensional nerve map of human bladder trigone","volume":"36","author":"Purves","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","article-title":"Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: A 20-year follow-up","volume":"90","author":"Jankovic","year":"2014","journal-title":"Toxicon"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.aju.2013.07.006","article-title":"Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches","volume":"11","author":"Osman","year":"2013","journal-title":"Arab. J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2006.01.005","article-title":"Botulinum toxin--new mechanisms, new therapeutic directions?","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_38","first-page":"420","article-title":"Application of methylene blue as an improvement of the injection technique of botulinum toxin a in the treatment of refractory idiopathic overactive bladder: Prospective, single-blind (patient-blind), randomized trial","volume":"14","author":"Szczypior","year":"2019","journal-title":"Wideochir Inne Tech Maloinwazyjne"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e009122","DOI":"10.1136\/bmjopen-2015-009122","article-title":"Comparative assessment of onabotulinumtoxina and mirabegron for overactive bladder: An indirect treatment comparison","volume":"6","author":"Freemantle","year":"2016","journal-title":"BMJ Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SPV.0000000000000914","article-title":"Early and consistent improvements in urinary symptoms and quality of life with onabotulinumtoxina in patients with overactive bladder and urinary incontinence: Results from a randomized, placebo-controlled, phase iv clinical trial","volume":"27","author":"McCammon","year":"2021","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"key":"ref_41","first-page":"79","article-title":"Onabotulinumtoxina for the treatment of overactive bladder","volume":"6","author":"Cox","year":"2014","journal-title":"Res. Rep. Urol."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/4\/207\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:46Z","timestamp":1760030326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/4\/207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["toxins17040207"],"URL":"https:\/\/doi.org\/10.3390\/toxins17040207","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}